Publications by authors named "Erin Yoder"

Claim this Profile
T
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.
Peter Blumencranz, Mehran Habibi, Steve Shivers, Geza Acs, Lisa E Blumencranz, Erin B Yoder

Ann Surg Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
James V Pellicane, Peter D Beitsch, David T Rock, Raye J Budway, Carrie L Dul, Erin B Yoder

Surg Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
Pat W Whitworth, Peter D Beitsch, Mary K Murray, Paul D Richards, Angela Mislowsky, Erin B Yoder

JCO Precis Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
Pat Whitworth, Peter D Beitsch, James V Pellicane, Paul L Baron, Laura A Lee, Erin B Yoder

Ann Surg Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
Pat W Whitworth, Peter D Beitsch, James V Pellicane, Paul L Baron, Laura A Lee, Erin B Yoder

JCO Precis Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Yuan, Jin Sun Lee, Susan E Yost, Sierra Min Li, Paul H Frankel, Erin Yoder

Oncologist· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers.
Floris H Groenendijk, Tina Treece, Erin Yoder, Paul Baron, Peter Beitsch

NPJ Breast Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures.
Peter Beitsch, Pat Whitworth, Paul Baron, James Pellicane, Tina Treece, Erin Yoder

Ann Surg Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis